Edition:
India

Alnylam Pharmaceuticals Reports Second Quarter 2019 Financial Results And Highlights Recent Period Activity


Tuesday, 6 Aug 2019 

Aug 6 (Reuters) - Alnylam Pharmaceuticals Inc ::ALNYLAM PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY.Q2 NON-GAAP LOSS PER SHARE $1.83.Q2 EARNINGS PER SHARE ESTIMATE $-1.86 -- REFINITIV IBES DATA.SEES 2019 ANNUAL NON-GAAP RESEARCH AND DEVELOPMENT EXPENSES TO BE IN RANGE OF $550 TO $575 MILLION.SEES 2019 NON-GAAP SG&A EXPENSES TO BE IN RANGE OF $390 TO $400.ALNYLAM PHARMACEUTICALS-CASH, CASH EQUIVALENTS, MARKETABLE DEBT SECURITIES WILL SUPPORT OPERATIONS FOR MULTIPLE YEARS BASED ON CURRENT OPERATING PLAN.LOWERS 2019 NON-GAAP RESEARCH AND DEVELOPMENT AND NON-GAAP SG&A EXPENSE GUIDANCE.ENDED Q2 WITH APPROXIMATELY $2.0 BILLION IN CASH.